High SHBG and Low Libido Despite High Total Testosterone

Understanding the Relationship Between SHBG, Testosterone, and Libido

• The European Association of Urology notes that low libido can occur despite high total testosterone when SHBG is elevated, as free testosterone is the bioactive form driving sexual function 1
• SHBG binds to testosterone, making it biologically inactive, and higher SHBG levels result in less free testosterone available for tissues, including brain centers regulating libido, as reported by the European Urology and Gut journals 2, 1
• The free testosterone index (total testosterone/SHBG ratio) is more predictive of hypogonadal symptoms than total testosterone alone, with a ratio <0.3 indicating functional hypogonadism, according to the Gut journal 2

Diagnostic Approach

• The European Urology journal recommends measuring calculated free testosterone to confirm functional hypogonadism, with morning blood draws for total testosterone, SHBG, and calculated free testosterone 1, 3
• Repeat testing is necessary to confirm the pattern, as single measurements can be misleading, as suggested by Praxis Medical Insights 3

Common Causes of Elevated SHBG

• Hyperthyroidism, liver disease, aging, medications (including oral estrogens and anticonvulsants), and low insulin states can increase SHBG production, as reported by Praxis Medical Insights and European Urology 3, 1

Management Approach

• If free testosterone is confirmed low, treatment options depend on the underlying cause, with first-line approaches including addressing hyperthyroidism, discontinuing medications that increase SHBG, and optimizing metabolic health, as recommended by Praxis Medical Insights and European Urology 1, 3
• Testosterone replacement therapy can improve sexual function with moderate-certainty evidence, producing small to moderate improvements in global sexual function and erectile function, as demonstrated by the Annals of Internal Medicine 4
• The American College of Physicians suggests that transdermal or intramuscular testosterone are both effective, with similar outcomes, and recommends monitoring SHBG and free testosterone levels after starting therapy 4

Testicular Atrophy Due to Low Free Testosterone

Understanding the Mechanism

• The European Association of Urology recognizes that SHBG binds testosterone and renders it biologically inactive, and only free testosterone can enter tissues and exert physiological effects, which is critical for maintaining testicular function and preventing atrophy 5, 6
• Elevated SHBG can prevent adequate free testosterone delivery to tissues, including the testes, brain centers regulating libido, and muscle, regardless of total testosterone measures, leading to functional hypogonadism 5

Clinical Significance for Atrophy

• Testicular atrophy requires sustained low intratesticular testosterone levels, and normal LH signaling should maintain reasonable testicular size unless there's primary testicular pathology or severe SHBG elevation 7
• Low free testosterone effects on peripheral tissues can cause muscle atrophy, reduced lean body mass, or loss of secondary sexual characteristics, which are consistent with symptomatic hypogonadism 5, 6
• A subset of men with elevated SHBG and normal total testosterone will have low free testosterone levels that cause symptomatic hypogonadism, particularly in men over 60 years old 5, 6

Diagnostic Confirmation Required

• Measuring calculated free testosterone by equilibrium dialysis is necessary to confirm functional hypogonadism, as total testosterone alone is insufficient and misses approximately half of diagnoses when SHBG is elevated 5

Management Algorithm

• The European Association of Urology guidelines recommend addressing reversible causes of low free testosterone, such as treating hyperthyroidism, discontinuing SHBG-elevating medications, and optimizing metabolic health and body composition 7
• Testosterone replacement therapy may be considered if free testosterone remains low after addressing reversible causes, with transdermal preparations being preferred for most patients 5
• Monitoring free testosterone levels 2-3 months after initiation of therapy is necessary to ensure adequate replacement 5

High SHBG and Functional Hypogonadism

Introduction to Functional Hypogonadism

• The European Association of Urology recognizes that functional hypogonadism from elevated SHBG causes symptomatic androgen deficiency even when total testosterone appears normal or high, leading to low libido and erectile dysfunction in men 8

Diagnostic Considerations

• In men presenting with erectile dysfunction, elevated SHBG can sequester most of their testosterone in an inactive bound form, and this pattern is frequently missed by screening protocols that measure only total testosterone, highlighting the importance of measuring free testosterone levels 8
• Liver function tests can help exclude chronic liver disease as a cause of elevated SHBG, which is a critical step in the diagnostic workup 8

Management of Functional Hypogonadism

• The European Association of Urology guidelines suggest that optimizing conditions that elevate SHBG, such as treating hyperthyroidism or discontinuing SHBG-elevating medications, should be the first step in management before considering testosterone replacement therapy 8

Elevated SHBG and Erectile Dysfunction

Diagnostic Considerations

• The European Association of Urology recognizes that SHBG elevation causes symptomatic androgen deficiency even when total testosterone appears normal or high, leading to low libido and erectile dysfunction 9
• Measuring calculated free testosterone is critical because total testosterone alone misses approximately half of diagnoses when SHBG is elevated, according to the American Diabetes Association 10

Treatment Approaches

• Testosterone replacement therapy can improve erectile function with moderate-certainty evidence, producing small to moderate improvements, as recommended by the American College of Physicians 11
• PDE5 inhibitors (sildenafil, tadalafil, vardenafil) remain first-line for ED regardless of testosterone status, with the American College of Physicians and the American Heart Association supporting their use 11, 12

Essential Diagnostic Steps

• Investigating causes of elevated SHBG is necessary, including checking thyroid function, reviewing medications, and performing liver function tests, as suggested by the European Association of Urology and the American Diabetes Association 9, 10

Testosterone Bioavailability and SHBG

Clinical Implications for Diagnosis

• The Endocrine Society recommends measuring free testosterone to avoid missing approximately half of hypogonadism diagnoses when SHBG is elevated, as total testosterone alone is insufficient for diagnosis 13
• Men with obesity and low total testosterone due solely to low SHBG typically have normal free testosterone levels and are not truly hypogonadal 13
• Obesity-related decreases in testosterone are frequently attributable to low SHBG concentrations 13
• A subset of obese men will have low free testosterone levels due to increased aromatization of testosterone to estradiol in adipose tissue, causing estradiol-mediated negative feedback that suppresses pituitary luteinizing hormone secretion 13

Diagnostic Algorithm

• When evaluating suspected hypogonadism, measure morning total testosterone, free testosterone by equilibrium dialysis, and SHBG levels, repeating if abnormal to confirm the pattern 13
• In obese patients, measurement of morning serum free testosterone is essential when total testosterone is low 13
• If testosterone levels are subnormal on repeat testing, measure serum LH and FSH to distinguish primary from secondary hypogonadism 13

Treatment Considerations

• Testosterone replacement should be considered only when morning free testosterone by equilibrium dialysis is low on at least 2 separate assessments 13
• Transdermal testosterone preparations are preferred due to stable day-to-day levels 13

Management of Elevated SHBG and Functional Hypogonadism in Men

SHBG Elevation and Functional Hypogonadism

• An SHBG concentration of ~100 nmol/L (reference 7‑50 nmol/L) indicates markedly increased testosterone‑binding capacity, rendering most circulating testosterone biologically unavailable. 14
• The free‑testosterone index (total testosterone ÷ SHBG) × 100 < 30 (or a total‑testosterone/SHBG ratio < 0.3) reliably identifies functional hypogonadism and predicts hypogonadal symptoms better than total testosterone alone. 14

Reversible Causes of Elevated SHBG (European Association of Urology recommendation)

• Hyperthyroidism – excess thyroid hormone stimulates hepatic SHBG synthesis; treatment of hyperthyroidism normalizes SHBG levels. 14
• Chronic liver disease / cirrhosis – hepatic dysfunction raises SHBG production; addressing the underlying liver pathology can reduce SHBG. 14
• Medications that raise SHBG – anticonvulsants, oral estrogens, and supratherapeutic thyroid hormone increase SHBG; discontinuation (when feasible) is a first‑step intervention. 14
• HIV infection – suboptimal antiretroviral therapy or HIV‑associated wasting can elevate SHBG; optimization of ART may lower SHBG. 14
• Aging – physiological aging modestly raises SHBG, but treatment is warranted only when free testosterone is demonstrably low. 14

Pharmacologic Agents That Lower SHBG (but are not primary strategies)

• Growth hormone – reduces SHBG concentrations but lacks indication for hypogonadism treatment. 14
• Glucocorticoids – lower SHBG yet induce secondary hypogonadism; therefore they are contraindicated in this context. 14
• Anabolic‑androgenic steroids – suppress endogenous testosterone while decreasing SHBG; use is contraindicated for functional hypogonadism. 14
• Testosterone replacement therapy – lowers SHBG as a secondary effect of restoring normal testosterone levels. 14

Testosterone Replacement Therapy (Evidence from Annals of Internal Medicine)

• In men with confirmed low free testosterone, testosterone replacement yields a small‑to‑moderate but statistically significant improvement in sexual function and libido (standardized mean difference ≈ 0.35), representing a clinically meaningful benefit. Evidence strength: moderate‑quality randomized data. 15
• The same therapy shows little to no impact on physical functioning, energy, vitality, depressive symptoms, or cognitive performance. Evidence strength: moderate‑quality randomized data. 15